Enliven Therapeutics (NASDAQ:ELVN) CFO Sells $303,006.30 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $50.35, for a total value of $303,006.30. Following the sale, the chief financial officer directly owned 38,000 shares of the company’s stock, valued at $1,913,300. This represents a 13.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl also recently made the following trade(s):

• On Monday, August 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The stock was sold at an average price of $58.58, for a total value of $352,534.44.
• On Friday, July 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The shares were sold at an average price of $52.64, for a total value of $316,787.52.

Enliven Therapeutics Trading Down 4.4%

Shares of NASDAQ:ELVN opened at $46.09 on Thursday. The stock has a 50 day moving average of $56.18 and a 200 day moving average of $46.56. The company has a market cap of $3.38 billion, a PE ratio of -27.60 and a beta of 0.30. Enliven Therapeutics, Inc. has a 12-month low of $14.78 and a 12-month high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Equities research analysts predict that Enliven Therapeutics, Inc. will post -1.69 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. JonesTrading upped their target price on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, June 29th. HC Wainwright raised their price target on Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, July 9th. Mizuho boosted their price objective on Enliven Therapeutics from $62.00 to $73.00 and gave the company an “outperform” rating in a research report on Tuesday, August 18th. William Blair initiated coverage on Enliven Therapeutics in a research note on Tuesday, August 18th. They issued an “outperform” rating for the company. Finally, Stifel Nicolaus increased their target price on Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Enliven Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $75.00.

Hedge Funds Weigh In On Enliven Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ELVN. BlackRock Inc. purchased a new position in Enliven Therapeutics during the second quarter valued at $221,255,000. First Light Asset Management LLC lifted its stake in Enliven Therapeutics by 574.1% in the 2nd quarter. First Light Asset Management LLC now owns 1,360,750 shares of the company’s stock worth $69,058,000 after purchasing an additional 1,158,883 shares in the last quarter. Siren L.L.C. purchased a new stake in Enliven Therapeutics in the 1st quarter worth $29,252,000. Jupiter Topco LLC bought a new position in shares of Enliven Therapeutics during the 2nd quarter valued at about $30,617,000. Finally, Affinity Asset Advisors LLC bought a new position in shares of Enliven Therapeutics during the 1st quarter valued at about $23,007,000. Institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for the treatment of cancer. The company applies a precision oncology approach, seeking to create targeted therapies that may offer improved efficacy, safety, durability and convenience compared with existing treatments.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for patients with chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for the treatment of HER2-driven solid tumors.